

References

R-5006-01

1. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP). 2009; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070306.pdf>. Accessed August 20, 2019.
2. Food and Drug Administration (FDA). PET Drugs - Current Good Manufacturing Practice (CGMP) Small Entity Compliance Guide. 2011; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM266640.pdf>. Accessed August 20, 2019.
3. Food and Drug Administration (FDA). Guidance: Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs. 2012; <https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291573.pdf>. Accessed August 20, 2019.
4. Food and Drug Administration (FDA). Positron Emission Tomography Drug Products; Safety and Effectiveness of Certain PET Drugs for Specific Indications. Federal Register. 2000;65(48):12999-13010.
5. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) in the Management of Seizure Disorders. TEC Assessments. 1996;Volume 11:Tab 33.
6. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) for the Assessment of Cerebrovascular Disease. TEC Assessments. 1996;Volume 11:Tab 35.
7. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Positron Emission Tomography (PET) of Central Nervous System Diseases. TEC Assessments. 1992;Volume 7:Tab 3.
8. Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. *N Engl J Med*. Sep 8 2011;365(10):919-926. PMID 21899452.
9. Mishra AM, Bai H, Gribizis A, et al. Neuroimaging biomarkers of epileptogenesis. *Neurosci Lett*. Jun 27 2011;497(3):194-204. PMID 21303682.
10. Engel J, Cascino G, Ness P, et al. Outcome with respect to epileptic seizures. In: Engel J, ed. *Surgical Treatment of the Epilepsies*. New York, NY: Raven Press; 1993:609-621.
11. Jones AL, Cascino GD. Evidence on use of neuroimaging for surgical treatment of temporal lobe epilepsy: a systematic review. *JAMA Neurol*. Apr 1 2016;73(4):464-470. PMID 26926529.

12. Wang X, Zhang C, Wang Y, et al. Prognostic factors for seizure outcome in patients with MRI-negative temporal lobe epilepsy: A meta-analysis and systematic review. *Seizure*. May 2016;38:54-62. PMID 27182689.
13. Burneo JG, Poon R, Kellett S, et al. The utility of positron emission tomography in epilepsy. *Can J Neurol Sci*. Nov 2015;42(6):360-371. PMID 26437611.
14. Englot DJ, Wang DD, Rolston JD, et al. Rates and predictors of long-term seizure freedom after frontal lobe epilepsy surgery: a systematic review and meta-analysis. *J Neurosurg*. May 2012;116(5):1042-1048. PMID 22304450.
15. Willmann O, Wennberg R, May T, et al. The contribution of 18F-FDG PET in preoperative epilepsy surgery evaluation for patients with temporal lobe epilepsy A meta-analysis. *Seizure*. Sep 2007;16(6):509-520. PMID 17532231.
16. Traub-Weidinger T, Weidinger P, Groppe G, et al. Presurgical evaluation of pediatric epilepsy patients prior to hemispherotomy: the prognostic value of 18F-FDG PET. *J Neurosurg Pediatr*. Dec 2016;25(6):683-688. PMID 27611898.
17. Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. Oct 1 2004;39(7):885-910. PMID 15472838.
18. Dinh MT, Abad CL, Safdar N. Diagnostic accuracy of the physical examination and imaging tests for osteomyelitis underlying diabetic foot ulcers: meta-analysis. *Clin Infect Dis*. Aug 15 2008;47(4):519-527. PMID 18611152.
19. Lauri C, Tamminga M, Glaudemans A, et al. Detection of osteomyelitis in the diabetic foot by imaging techniques: a systematic review and meta-analysis comparing MRI, white blood cell scintigraphy, and FDG-PET. *Diabetes Care*. Aug 2017;40(8):1111-1120. PMID 28733376.
20. Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic performance of Fluorine-18-Fluorodeoxyglucose positron emission tomography for the diagnosis of osteomyelitis related to diabetic foot: a systematic review and a meta-analysis. *Foot (Edinb)*. Dec 2013;23(4):140-148. PMID 23906976.
21. Termaat MF, Raijmakers PG, Scholten HJ, et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. *J Bone Joint Surg Am*. Nov 2005;87(11):2464-2471. PMID 16264122.
22. de Winter F, van de Wiele C, Vogelaers D, et al. Fluorine-18 fluorodeoxyglucose-positron emission tomography: a highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. *J Bone Joint Surg Am*. May 2001;83-A(5):651-660. PMID 11379733.
23. Schiesser M, Stumpe KD, Trentz O, et al. Detection of metallic implant-associated infections with FDG PET in patients with trauma: correlation with microbiologic results. *Radiology*. Feb 2003;226(2):391-398. PMID 12563131.

24. Guhlmann A, Brecht-Krauss D, Suger G, et al. Fluorine-18-FDG PET and technetium-99m antigranulocyte antibody scintigraphy in chronic osteomyelitis. *J Nucl Med*. Dec 1998;39(12):2145-2152. PMID 9867159.
25. Meller J, Koster G, Liersch T, et al. Chronic bacterial osteomyelitis: prospective comparison of (18)F-FDG imaging with a dual-head coincidence camera and (111)In-labelled autologous leucocyte scintigraphy. *Eur J Nucl Med Mol Imaging*. Jan 2002;29(1):53-60. PMID 11807607.
26. Rastogi A, Bhattacharya A, Prakash M, et al. Utility of PET/CT with fluorine-18-fluorodeoxyglucose-labeled autologous leukocytes for diagnosing diabetic foot osteomyelitis in patients with Charcot's neuroarthropathy. *Nucl Med Commun*. Dec 2016;37(12):1253-1259. PMID 27749777.
27. Smailagic N, Vacante M, Hyde C, et al. (1)(8)F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). *Cochrane Database Syst Rev*. Jan 28 2015;1:CD010632. PMID 25629415.
28. Davison CM, O'Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. *Int J Geriatr Psychiatry*. Jun 2014;29(6):551-561. PMID 24123413.
29. Bloudek LM, Spackman DE, Blankenburg M, et al. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer's disease. *J Alzheimers Dis*. Jun 2011;26(4):627-645. PMID 21694448.
30. Yuan Y, Gu ZX, Wei WS. Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis. *AJNR Am J Neuroradiol*. Feb 2009;30(2):404-410. PMID 19001534.
31. Matchar DB, Kulasingam SL, McCrory DC, et al. *Use of Positron Emission Tomography and Other Neuroimaging Techniques in the Diagnosis and Management of Alzheimer's Disease and Dementia*. Rockville, MD: Agency for Healthcare Research and Quality; 2001.
32. Pagani M, Nobili F, Morbelli S, et al. Early identification of MCI converting to AD: a FDG PET study. *Eur J Nucl Med Mol Imaging*. Nov 2017;44(12):2042-2052. PMID 28664464.
33. Motara H, Olusoga T, Russell G, et al. Clinical impact and diagnostic accuracy of 2-[18F]-fluoro-2-deoxy-d- glucose positron-emission tomography/computed tomography (PET/CT) brain imaging in patients with cognitive impairment: a tertiary centre experience in the UK. *Clin Radiol*. Jan 2017;72(1):63-73. PMID 27637430.
34. Gulati A, Bagga A. Large vessel vasculitis. *Pediatr Nephrol*. Jun 2010;25(6):1037-1048. PMID 19844748.

35. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. *Arthritis Rheum.* Aug 1990;33(8):1129-1134. PMID 1975175.
36. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. *Arthritis Rheum.* Aug 1990;33(8):1122-1128. PMID 2202311.
37. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. *Arthritis Rheum.* Jan 2013;65(1):1-11. PMID 23045170.
38. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. *Ann Rheum Dis.* Mar 2009;68(3):318-323. PMID 18413441.
39. Lee YH, Choi SJ, Ji JD, et al. Diagnostic accuracy of 18F-FDG PET or PET/CT for large vessel vasculitis : A meta-analysis. *Z Rheumatol.* Nov 2016;75(9):924-931. PMID 26704559.
40. Soussan M, Nicolas P, Schramm C, et al. Management of large-vessel vasculitis with FDG-PET: a systematic literature review and meta-analysis. *Medicine (Baltimore).* Apr 2015;94(14):e622. PMID 25860208.
41. Puppo C, Massollo M, Paparo F, et al. Giant cell arteritis: a systematic review of the qualitative and semiquantitative methods to assess vasculitis with 18F-fluorodeoxyglucose positron emission tomography. *Biomed Res Int.* Sep 2014;2014:574248. PMID 25254211.
42. Treglia G, Mattoli MV, Leccisotti L, et al. Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review. *Clin Rheumatol.* Oct 2011;30(10):1265-1275. PMID 21833685.
43. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of (1)(8)F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* Sep 2011;38(9):1764-1772. PMID 21559981.
44. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. *Ann Intern Med.* Jun 1 1994;120(11):919-929. PMID 7909656.
45. Gupta A, Baradaran H, Schweitzer AD, et al. Oxygen extraction fraction and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. *AJNR Am J Neuroradiol.* Feb 2014;35(2):250-255. PMID 23945227.
46. Yan J, Zhang C, Niu Y, et al. The role of 18F-FDG PET/CT in infectious endocarditis: a systematic review and meta-analysis. *Int J Clin Pharmacol Ther.* May 2016;54(5):337-342. PMID 27008000.

47. Mackie SL, Koduri G, Hill CL, et al. Accuracy of musculoskeletal imaging for the diagnosis of polymyalgia rheumatica: systematic review. *RMD Open*. Nov 2015;1(1):e000100. PMID 26535139.
48. Hao R, Yuan L, Kan Y, et al. Diagnostic performance of 18F-FDG PET/CT in patients with fever of unknown origin: a meta-analysis. *Nucl Med Commun*. Jul 2013;34(7):682-688. PMID 23636293.
49. Besson FL, Chaumet-Riffaud P, Playe M, et al. Contribution of (18)F-FDG PET in the diagnostic assessment of fever of unknown origin (FUO): a stratification-based meta-analysis. *Eur J Nucl Med Mol Imaging*. Sep 2016;43(10):1887-1895. PMID 27037917.
50. Bharucha T, Rutherford A, Skeoch S, et al. Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. *Clin Radiol*. Sep 2017;72(9):764-771. PMID 28600002.
51. Kapoor RR, James C, Hussain K. Advances in the diagnosis and management of hyperinsulinemic hypoglycemia. *Nat Clin Pract Endocrinol Metab*. Feb 2009;5(2):101-112. PMID 19165222.
52. Yang J, Hao R, Zhu X. Diagnostic role of 18F-dihydroxyphenylalanine positron emission tomography in patients with congenital hyperinsulinism: a meta-analysis. *Nucl Med Commun*. Apr 2013;34(4):347-353. PMID 23376859.
53. Prodromou ML, Ziakas PD, Poulou LS, et al. FDG PET is a robust tool for the diagnosis of spondylodiscitis: a meta-analysis of diagnostic data. *Clin Nucl Med*. Apr 2014;39(4):330-335. PMID 24445277.
54. Treglia G, Taralli S, Calcagni ML, et al. Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. *J Comput Assist Tomogr*. May-Jun 2011;35(3):387-393. PMID 21586936.
55. Caobelli F, Cobelli M, Pizzocaro C, et al. The role of neuroimaging in evaluating patients affected by Creutzfeldt- Jakob disease: a systematic review of the literature. *J Neuroimaging*. Jan 2015;25(1):2-13. PMID 24593302.
56. Saleem BR, Pol RA, Slart RH, et al. 18F-Fluorodeoxyglucose positron emission tomography/CT scanning in diagnosing vascular prosthetic graft infection. *Biomed Res Int*. Sep 2014;2014:471971. PMID 25210712.
57. Jin H, Yuan L, Li C, et al. Diagnostic performance of FDG PET or PET/CT in prosthetic infection after arthroplasty: a meta-analysis. *Q J Nucl Med Mol Imaging*. Mar 2014;58(1):85-93. PMID 24469570.
58. Zhang J, Li LF, Zhu YJ, et al. Diagnostic performance of 18F-FDG-PET versus scintigraphy in patients with inflammatory bowel disease: a meta-analysis of prospective literature. *Nucl Med Commun*. Dec 2014;35(12):1233-1246. PMID 25192191.

59. Niccolini F, Politis M. A systematic review of lessons learned from PET molecular imaging research in atypical parkinsonism. *Eur J Nucl Med Mol Imaging*. Nov 2016;43(12):2244-2254. PMID 27470326.
60. Pagano G, Niccolini F, Politis M. Current status of PET imaging in Huntington's disease. *Eur J Nucl Med Mol Imaging*. Jun 2016;43(6):1171-1182. PMID 26899245.
61. Yin Y, Liu X, Yang X, et al. Diagnostic value of FDG-PET versus magnetic resonance imaging for detecting spondylitis: a systematic review and meta-analysis. *Spine J*. 2018 Dec;18(12):2323-2332. PMID: 30121323.
62. Treglia G, Taralli S, Giordano A. Emerging role of whole-body 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. *Sarcoidosis Vasc Diffuse Lung Dis*. Oct 2011;28(2):87-94. PMID 22117499.
63. Kwee TC, Kwee RM, Alavi A. FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. *Eur J Nucl Med Mol Imaging*. Nov 2008;35(11):2122-2132. PMID 18704405.
64. Reinartz P. FDG-PET in patients with painful hip and knee arthroplasty: technical breakthrough or just more of the same. *Q J Nucl Med Mol Imaging*. Feb 2009;53(1):41-50. PMID 19182727.
65. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. May 8 2001;56(9):1143-1153. PMID 11342678.
66. Petersen RC, Stevens JC, Ganguli M, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. May 8 2001;56(9):1133-1142. PMID 11342677.
67. Suchowersky O, Reich S, Perlmutter J, et al. Practice Parameter: diagnosis and prognosis of new onset Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Apr 11 2006;66(7):968-975. PMID 16606907.
68. Aarsland D, Emre M, Lees A, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. Jan 2 2007;68(1):80; author reply 81. PMID 17200503.
69. American Academy of Neurology. Guideline Summary: Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. 2018;

<https://www.aan.com/Guidelines/home/GetGuidelineContent/887>. Accessed July 20, 2019.

70. American Academy of Orthopaedic Surgeons (AAOS). The diagnosis of periprosthetic joint infections of the hip and knee: guideline and evidence report. 2010; <https://www.aaos.org/research/guidelines/PJIguideline.pdf>. Accessed 20, 2019.
71. Expert Panel on Musculoskeletal Imaging, Beaman FD, von Herrmann PF, et al. ACR Appropriateness Criteria(R) suspected osteomyelitis, septic arthritis, or soft tissue infection (excluding spine and diabetic foot). *J Am Coll Radiol*. May 2017;14(5S):S326-S337. PMID 28473089.
72. American College of Radiology (ACR). ACR appropriateness criteria: dementia and movement disorders. 2015; <https://acsearch.acr.org/list>. Accessed August 20, 2019.
73. Frey KA, Lodge MA, Meltzer CC, et al. ACR-ASNR practice parameter for brain PET/CT imaging dementia. *Clin Nucl Med*. Feb 2016;41(2):118-125. PMID 26646994.
74. American College of Radiology (ACR). ACR appropriateness criteria: imaging after total knee arthroplasty. 2017; <https://acsearch.acr.org/list>. Accessed August 20, 2019.
75. American College of Radiology (ACR). ACR appropriateness criteria: seizures and epilepsy. 2014; <https://acsearch.acr.org/list>. Accessed August 20, 2019.
76. American College of Radiology (ACR). ACR appropriateness criteria: Crohn disease. 2014; <https://acsearch.acr.org/list>. Accessed August 20, 2019.
77. American College of Radiology (ACR). ACR appropriateness criteria: fever without source or unknown origin-- child. 2019; <https://acsearch.acr.org/docs/69340/Narrative/> Accessed July 20, 2019.
78. American College of Radiology (ACR). ACR appropriateness criteria: suspected osteomyelitis of the foot in patients with diabetes mellituse: 2012. 2012; <https://acsearch.acr.org/list>. Accessed August 20, 2019.
79. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. *Clin Infect Dis*. Sep 15 2015;61(6):e26-46. PMID 26229122.
80. Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. *Clin Infect Dis*. Jan 2013;56(1):e1-e25. PMID 23223583.
81. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. *Clin Infect Dis*. Jun 2012;54(12):e132-173. PMID 22619242.
82. Centers for Medicare & Medicaid Services (CMS). Decision Memo for Positron Emission Tomography (FDG) and Other Neuroimaging Devices for

Suspected Dementia (CAG-00088R). 2004; [https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+\(FDG\)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+\(1st+Recon\)&bc=AiAAAAAAEAAA&](https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=104&NcaName=Positron+Emission+Tomography+(FDG)+and+Other+Neuroimaging+Devices+for+Suspected+Dementia+(1st+Recon)&bc=AiAAAAAAEAAA&). Accessed August 20, 2019.

83. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination (NCD) for FDG PET for Dementia and Neurodegenerative Diseases (220.6.13). 2009; <https://www.cms.gov/medicare-coverage-database/search/document-id-search-results.aspx?DocID=220.6.13&bc=IAAAAAAAAAAAAA&&SearchType=Advanced>. Accessed August 20, 2019.
84. Centers for Medicare & Medicaid Services (CMS). National Coverage Determination for FDG PET for Infection and Inflammation (220.6.16). 2008; https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=323&ncdver=1&DocID=220.6.16&ncd_id=220.6.16&ncd_version=1&basket=ncd%25253A220%25252E6%25252E16%25253A1%25253AFDG+PET+for+Infection+and+Inflammation&bc=gAAAAAgAAAAAA%3D%3D&. Accessed August 20, 2019.